Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $13.1429.

A number of research analysts recently weighed in on JSPR shares. UBS Group started coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. Finally, TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Propel Bio Management LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth approximately $2,449,000. Kingdon Capital Management L.L.C. increased its position in Jasper Therapeutics by 93.5% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock worth $3,153,000 after buying an additional 640,138 shares during the period. Knott David M Jr acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $408,000. Readystate Asset Management LP acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $234,000. Finally, XTX Topco Ltd acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $152,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Stock Performance

Shares of JSPR stock opened at $0.46 on Wednesday. The stock’s 50 day simple moving average is $0.81 and its 200 day simple moving average is $1.25. Jasper Therapeutics has a twelve month low of $0.42 and a twelve month high of $7.19. The company has a market capitalization of $12.81 million, a price-to-earnings ratio of -0.14 and a beta of 3.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. On average, analysts forecast that Jasper Therapeutics will post -1.81 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.